Literature DB >> 17682903

Equine bronchoalveolar lavage cytokines in the development of recurrent airway obstruction.

M Pietra1, A Peli, A Bonato, A Ducci, S Cinotti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17682903     DOI： 10.1007/s11259-007-0055-y

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN： 0165-7380            Impact factor:   2.459


× No keyword cloud information.
  8 in total

1.  Cytokine profiles of peripheral blood and airway CD4 and CD8 T lymphocytes in horses with recurrent airway obstruction.

Authors:  C Kleiber; B C McGorum; D W Horohov; R S Pirie; A Zurbriggen; R Straub
Journal:  Vet Immunol Immunopathol       Date:  2005-03-10       Impact factor: 2.046

2.  Evaluation of cytokine production by equine alveolar macrophages exposed to lipopolysaccharide, Aspergillus fumigatus, and a suspension of hay dust.

Authors:  Tamarinde T J M Laan; Sarah Bull; R Scott Pirie; Johanna Fink-Gremmels
Journal:  Am J Vet Res       Date:  2005-09       Impact factor: 1.156

3.  Cytokine induction in pulmonary airways of horses with heaves and effect of therapy with inhaled fluticasone propionate.

Authors:  Steeve Giguère; Laurent Viel; Elise Lee; Robert J MacKay; Jorge Hernandez; Marco Franchini
Journal:  Vet Immunol Immunopathol       Date:  2002-03       Impact factor: 2.046

4.  Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile.

Authors:  J P Lavoie; K Maghni; M Desnoyers; R Taha; J G Martin; Q A Hamid
Journal:  Am J Respir Crit Care Med       Date:  2001-10-15       Impact factor: 21.405

5.  A novel model for equine recurrent airway obstruction.

Authors:  K S Bowles; R E Beadle; S Mouch; S S Pourciau; M A Littlefield-Chabaud; C Le Blanc; L Mistric; D Fermaglich; D W Horohov
Journal:  Vet Immunol Immunopathol       Date:  2002-09-10       Impact factor: 2.046

6.  Interleukin-4 and interferon-gamma gene expression in summer pasture-associated obstructive pulmonary disease affected horses.

Authors:  R E Beadle; D W Horohov; S D Gaunt
Journal:  Equine Vet J       Date:  2002-07       Impact factor: 2.888

7.  IL-4, IL-5 and IFN-gamma mRNA expression in pulmonary lymphocytes in equine heaves.

Authors:  Marie-Eve Cordeau; Philippe Joubert; Oday Dewachi; Qutayba Hamid; Jean-Pierre Lavoie
Journal:  Vet Immunol Immunopathol       Date:  2004-01       Impact factor: 2.046

8.  Recurrent airway obstruction (RAO) in horses is characterized by IFN-gamma and IL-8 production in bronchoalveolar lavage cells.

Authors:  Dorothy M Ainsworth; Gabriele Grünig; Mary Beth Matychak; Jean Young; Bettina Wagner; Hollis N Erb; Douglas F Antczak
Journal:  Vet Immunol Immunopathol       Date:  2003-11-15       Impact factor: 2.046
  8 in total
  4 in total

1.  Increased apoptosis of CD4 and CD8 T lymphocytes in the airways of horses with recurrent airway obstruction.

Authors:  Gabriel Moran; Virginia A Buechner-Maxwell; Hugo Folch; Claudio Henriquez; Juan S Galecio; Barbara Perez; Cristian Carrasco; Miguel Barria
Journal:  Vet Res Commun       Date:  2011-05-19       Impact factor: 2.459

2.  Procalcitonin as a biomarker in equine chronic pneumopathies.

Authors:  Ann Kristin Barton; Anna Pelli; Martin Rieger; Heidrun Gehlen
Journal:  BMC Vet Res       Date:  2016-12-09       Impact factor: 2.741

3.  Immunohistochemical Expression of Neurokinin-A and Interleukin-8 in the Bronchial Epithelium of Horses with Severe Equine Asthma Syndrome during Asymptomatic, Exacerbation, and Remission Phase.

Authors:  Maria Morini; Angelo Peli; Riccardo Rinnovati; Giuseppe Magazzù; Noemi Romagnoli; Alessandro Spadari; Marco Pietra
Journal:  Animals (Basel)       Date:  2021-05-12       Impact factor: 2.752

4.  An Integrative miRNA-mRNA Expression Analysis Reveals Striking Transcriptomic Similarities between Severe Equine Asthma and Specific Asthma Endotypes in Humans.

Authors:  Matthias F Hulliger; Alicja Pacholewska; Amandine Vargas; Jean-Pierre Lavoie; Tosso Leeb; Vincent Gerber; Vidhya Jagannathan
Journal:  Genes (Basel)       Date:  2020-09-28       Impact factor: 4.096
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.